Compare FOUR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOUR | VERA |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.2B |
| IPO Year | 2020 | 2021 |
| Metric | FOUR | VERA |
|---|---|---|
| Price | $44.75 | $35.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 10 |
| Target Price | $79.05 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | N/A |
| Revenue This Year | $23.83 | N/A |
| Revenue Next Year | $14.30 | $472.48 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $39.91 | $18.76 |
| 52 Week High | $107.16 | $56.05 |
| Indicator | FOUR | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.83 | 31.52 |
| Support Level | $43.32 | $22.10 |
| Resistance Level | $51.65 | $42.77 |
| Average True Range (ATR) | 2.37 | 1.95 |
| MACD | -0.10 | -0.70 |
| Stochastic Oscillator | 18.06 | 2.75 |
Shift4 Payments Inc is an independent provider of software and payment processing solutions in the U.S., expanding internationally. Its payments platform offers integrated products and services across in-store, online, mobile and tablet-based channels, including end-to-end payment processing, merchant acquiring services, a proprietary omni-channel gateway, eCommerce capabilities, and reporting tools. The company distributes its services through internal sales teams and partners, including independent software vendors (ISVs) and value-added resellers (VARs). Revenue is predominantly recurring, derived mainly from processing fees and subscription revenue from POS software, business intelligence tools and other technology solutions. The company derives maximum revenue from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.